参考文献/References:
[1].Galassi AR,Werner GS,Boukhris M,et al. Percutaneous recanalisation of chronic total occlusions:2019 consensus document from the EuroCTO Club[J]. EuroIntervention,2019,15(2):198-208.
[2].Fefer P,Knudtson ML,Cheema AN,et al. Current perspectives on coronary chronic total occlusions:the Canadian Multicenter Chronic Total Occlusions Registry[J]. J Am Coll Cardiol,2012,59(11):991-997.
[3].Azzalini L,Jolicoeur EM,Pighi M,et al. Epidemiology,management strategies,and outcomes of patients with chronic total coronary occlusion[J]. Am J Cardiol,2016,118(8):1128-1135.
[4].Tajti P,Karmpaliotis D,Alaswad K,et al. The hybrid approach to chronictotalocclusion percutaneouscoronaryintervention:update from the PROGRESS CTO registry[J]. JACC Cardiovasc Interv,2018,11(14):1325-1335.
[5].Mahadevan K,Cosgrove C,Strange JW,et al. Factors influencing s tent failure in chronic total occlusion coronary intervention[J]. Interv Cardiol,2021,16:e27.
[6].Kato M,Kimura T,Morimoto T,et al. Comparison of five-year outcome of sirolimus-eluting stent implantation for chronic total occlusions versus for non-chronic total occlusion(from the j-Cypher registry)[J]. Am J Cardiol,2012,110(9):1282-1289.
[7].Brilakis ES,Mashayekhi K,Tsuchikane E,et al. Guiding principles for chronic total occlusion percutaneous coronary intervention[J]. Circulation,2019,140(5):420-433.
[8].Cortese B,Buccheri D,Piraino D,et al. Drug-coated balloon angioplasty: an intriguing alternative for the treatment of coronary chronic total occlusions[J]. Int J Cardiol,2015,187:238-239.
[9].Giacoppo D,Alfonso F,Xu B,et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis[J]. J Am Coll Cardiol,2020,75(21):2664-2678.
[10].Jeger RV,Eccleshall S,Wan Ahmad WA,et al. Drug-coated balloons for coronaryartery disease:third report of the I nternational?DCBConsensus Group[J]. JACC Cardiovasc Interv,2020,13(12):1391-1402.
[11].Tesfamariam B. Local arterial wall drug delivery using balloon catheter system[J]. J Control Release,2016,238:149-156.
[12].Cortese B,Bertoletti A. Paclitaxel coated balloons for coronary artery interventions:a comprehensive review of preclinical and clinical data[J]. Int J Cardiol,2012,161(1):4-12.
[13].Clever YP,Peters D,Calisse J,et al. Novel sirolimus-coated balloon catheter:in vivo evaluation in a porcine coronary model[J]. Circ Cardiovasc Interv,2016,9(4):e003543.
[14].Madanchi M,Cioffi GM,Attinger-Toller A,et al. Metal free percutaneous coronary interventions in all-comers:first experience with a novel sirolimus-coated balloon[J]. Cardiol J,2022,29(6):906-916.
[15].Linn YL,Choke ETC,Yap CJQ,et al Utility of sirolimus coated balloons in the peripheral vasculature—A review of the current literature [J]. CVIR Endovasc,2022,5(1):29.
[16].Wang X,Yang X,Lu W,et al. Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in de novo?coronary chronic total occlusion intervention:a multicenter observational study [J]. Front Cardiovasc Med,2023,10:1045859.
[17].K?ln PJ,Scheller B,Liew HB,et al. Treatment of chronic total occlusions in native coronary arteries by drug-coated balloons without stenting —A feasibility and safety study [J]. Int J Cardiol,2016,225:262-267.
[18].Jun EJ,Shin ES,Teoh EV,et al. Clinical outcomes of drug-coated balloon treatment after successful revascularization ofde novochronic total occlusions[J]. Front Cardiovasc Med,2022,9:821380.
[19].Wickramarachchi U,Corballis NH,Maart CA,et al. 24Drug coated balloon-only angioplasty in chronic total occlusions,a UK single centre experience[J]. Br Heart J,2017,103(suppl 7):A11-.
[20].Azzalini L,Karmpaliotis D,Santiago R,et al. Contemporary issues in chronic totalocclusion percutaneouscoronary intervention[J]. JACC Cardiovasc Interv,2022,15(1):1-21.
[21].Buccheri D,Lombardo RM,Cortese B. Drug-coated balloons for coronary artery disease:current concepts and controversies[J]. Future Cardiol,2019,15(6):437-454.
[22].Alfonso F,Scheller B. State of the art:balloon catheter technologies—Drug-coated balloon[J]. EuroIntervention,2017,13(6):680-695.
[23].Konishi H,Habara M,Nasu K,et al. Impact of optimal preparation before drug-coated balloon dilatation for de novo l esion in patients with coronary artery disease[J]. Cardiovasc Revasc Med,2022,35:91-95.
[24].Cortese B,Sanchez-Jimenez E. Back to the future:DCB use instead of DES for the treatment of complex,native coronary artery disease[J]. Eur Heart J Suppl,2021,23(suppl E):E63-E67.
[25].Cortese B,Berti S,Biondi-Zoccai G,et al. Drug-coated balloon treatment of coronary artery disease:a position paper of the Italian Society of Interventional Cardiology[J]. Catheter Cardiovasc Interv,2014,83(3):427-435.
[26].Iosif X,Peter T,Dimitri K,et al. Intravascular imaging for chronic total occlusion intervention[J]. Curr Cardiovasc Imaging Rep,2018,11(12):1-11.
[27].Kang J,Cho YS,Kim SW,et al. Intravascular ultrasound and angiographic predictors of in-stent restenosis of chronic total occlusion lesions[J]. PLoS One,2015,10(10):e0140421.
[28].Cortese B,di Palma G,Guimaraes MG,et al. Drug- coated balloon versus drug-eluting stent for small coronary vessel disease:PICCOLETOⅡ r andomized clinical trial[J]. JACC Cardiovasc Interv,2020,13(24):2840-2849.
[29].Xhepa E,Cassese S,Rroku A,et al. Subintimal versus intraplaque recanalization of coronary chronictotalocclusions:mid-termangiographic and OCT findings from?the?ISAR-OCT-CTO registry[J]. JACC Cardiovasc Interv,2019,12(19):1889-1898.
相似文献/References:
[1]郭云飞 柳景华.冠状动脉慢性完全闭塞合并分叉病变介入治疗[J].心血管病学进展,2020,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.003]
GUO Yunfei,LIU Jinghua.Percutaneous Coronary Intervention for Chronic Total Occlusion with Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2020,(1):7.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.003]
[2]牛梦瑶 胡晓惠 张静.冠状动脉小血管病变中药物球囊的应用进展[J].心血管病学进展,2022,(1):68.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.018]
NIU Mengyao,HU Xiaohui,ZHANG Jing.Application of Drug Balloon in Coronary Small Vessel Disease[J].Advances in Cardiovascular Diseases,2022,(1):68.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.018]
[3]赵代鑫?胡晓军?谭巨浪?裴畅.基于Meta分析对比药物涂层球囊与药物洗脱支架在细小冠状动脉疾病中的应用[J].心血管病学进展,2022,(1):82.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.021]
ZHAO Daixin,HU Xiaojun,TAN Julang,et al.Comparison of Application of Drug-Coated Balloon and Drug-Eluting Stent in Small Coronary Artery Disease Based on Meta Analysis[J].Advances in Cardiovascular Diseases,2022,(1):82.[doi:10.16806/j.cnki.issn.1004-3934.2022.01.021]
[4]刘文 魏芳晶.药物涂层球囊在真性分叉病变中的研究进展[J].心血管病学进展,2022,(6):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
LIU WenWEI Fangjing.Study of Drug-Coated?Balloon in?rue Coronary Bifurcation Lesions[J].Advances in Cardiovascular Diseases,2022,(1):511.[doi:10.16806/j.cnki.issn.1004-3934.2022.06.008]
[5]袁晓航 冯欢欢 高磊.复发性支架内再狭窄的研究进展[J].心血管病学进展,2022,(8):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]
YUAN Xiaohang FENG Huanhuan GAO Lei.Recurrent In-Stent Restenosis[J].Advances in Cardiovascular Diseases,2022,(1):677.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.002]
[6]仲昕 葛雷 葛均波.当代冠状动脉慢性完全闭塞病变介入治疗流程图解读及对比[J].心血管病学进展,2023,(2):107.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.003]
ZHONG XinGE LeiGE Junbo.Analysis and Comparison of Contemporary CTO-PCI Algorithm[J].Advances in Cardiovascular Diseases,2023,(1):107.[doi:10.16806/j.cnki.issn.1004-3934.2023.02.003]